Intestinal bacteria have been shown to be important in regulating host intermediary metabolism and contribute to obesity. However, relatively less in known about the effect of intestinal bacteria on the expression of hepatic drug processing genes of the host.
We may be born 100% human but will die 90% bacterial-a truly complex organism!" (Goodacre, 2007) . This statement reflects the fact that the human body has 10 times more bacterial cells than human cells. These bacteria grow and divide inside the intestinal lumen alongside ingested food, drugs, bile, and GI secretions. To survive,
intestinal bacteria have to metabolize food, bile, etc to extract energy from them. In general the host liver provides an ideal environment for oxidation and conjugation reactions, making polar and high-molecular-weight metabolites, whereas the intestinal bacteria provides an environment suited for reduction and hydrolysis reactions, making nonpolar and lower-molecular-weight metabolites (Sousa et al., 2008) . These intestinal bacterial enzymes, metabolize drugs as well as some endobiotic substances, such as conjugated hormones, bilirubin and bile acids.
Intestinal bacterial metabolism of orally administered drugs can alter their efficacy and clearance. For example, a specific intestinal bacteria Eggerthella lenta has the genetic machinery needed to inactivate the cardiac glycoside digoxin, and antibiotic administration increases serum digoxin concentrations (Lindenbaum et al., 1981; Saha et al., 1983) . Bacteria in the colon cleaves prodrug sulfasalazine to 5-aminosalicylic acid (anti-inflammatory drug) and sulfapyridine (antibiotic) and ampicillin administration decreases the concentration of sulfapyridine in circulation (Houston et al., 1982) .
Hepatic phase-1 drug metabolizing enzymes perform oxidation, reduction and hydrolysis reactions of drugs, and phase-2 drug metabolizing enzymes perform conjugation reactions. While the action of hepatic enzymes generally make the drugs more hydrophilic, the enzymes of intestinal bacteria often make the drug more D M D # 6 3 5 4 5 5 hydrophobic by deconjugating the conjugated drug metabolites, favoring intestinal uptake and increasing the half-life of drugs (Stojancevic et al., 2013) .
Intestinal bacteria, in addition to their direct effects on drug metabolism, can also alter the expression of hepatic drug metabolizing enzymes of the host. Bacterial infections are known to down-regulate the expression and activities of drug metabolizing enzymes, such as the Cyps (Morgan, 1997) . Endotoxin of common gram-negative bacteria, when injected into rats, decrease hepatic drug metabolism and Cyp expression (Ueyama et al., 2005) . Oral antibiotics, such as ciprofloxacin, can alter the metabolism of other drugs co-administered to the host (Xie et al., 2003) . Ciprofloxacin decreases the intestinal bacteria that make the secondary bile acid lithocholic acid, and thus decreases activation of the nuclear receptor pregnane X receptor and lowers Cyp3a expression in livers (Staudinger et al., 2001 ).
The drug metabolizing capacity of an individual varies not only because of polymorphisms in genes encoding host drug metabolizing enzymes and chemicals that induce or inhibit these enzymes, but also probably because of individual differences in intestinal bacterial species. Further, therapeutic modulation of intestinal bacteria by probiotics, prebiotics, and by fecal microbiota transplantation has the potential to alter the drug metabolizing capacity of the host, and thus affect the pharmacokinetics and pharmacodynamics of orally administered drugs taken simultaneously by the host.
Thus, there is a need to identify drug metabolizing enzymes that are altered by intestinal bacteria. Studying Germ-free (GF) mice that have no intestinal bacteria will reveal target genes that are likely to be regulated by intestinal bacteria. GF mice are born and raised inside sterile isolators and receive sterile food, water, bedding, etc. Previous studies
6 have demonstrated that certain drug metabolizing enzymes are altered in livers of GF mice (Bjorkholm et al., 2009; Toda et al., 2009) , which provided the first evidence that the xenobiotic-processing pathways of the host are targeted by intestinal microbiota.
However, there lacks a systematic and quantitative determination of all DPGs, including phase-I and phase-II drug metabolizing enzymes as well as transporters in liver. RNASeq provides a "true quantification" of transcripts and thus is an unbiased method of quantifying and comparing mRNA abundance of multiple genes (Cui et al., 2012) .
Therefore, the purpose of this study was to determine the alterations in hepatic drug metabolizing enzymes at the transcriptome level in GF mice as compared to conventional (CV) mice. This was accomplished by comparing the mRNA of hepatic phase-1 and phase-2 drug metabolizing enzymes in livers of GF-and CV-male mice using RNA-Seq.
MATERIALS AND METHODS

Animals
All mice used in the studies were males, between 2-3 months of age, n = 3/goup, and were housed in an AAALAC (Association for Assessment and Accreditation of Laboratory Animal Care International)-accredited facility at the University of Kansas Medical Center, with a 14-h light/10-h dark-cycle, in a temperature and humiditycontrolled environment, and with ad libitum access to water. The initial breeding colony of GF C57BL/6J/UNC mice was established with mice purchased from the National Gnotobiotic Rodent Resource Center (University of North Carolina, Chapel Hill). All conventional mice were purchased from Jackson Laboratories and received autoclaved rodent diet and autoclaved water for a week before and during the study. All animal 
Reagents
The monoclonal mouse anti-rat Cyp2b1/2b2 antibody, which also detects mouse Cyp2b10, was purchased from Santa Cruz Biotechnology, Inc (Santa Cruz, CA). A Cyp3a11 antibody was a generous gift from Dr. Xiaochao Ma (University of Pittsburgh).
Secondary antibodies were purchased from Sigma-Aldrich (St. Louis, MO). All other chemicals and reagents, unless indicated otherwise, were purchased from SigmaAldrich (St. Louis, MO).
Animal sacrifice and tissue collection
All animal sacrifices and tissue collections were performed between 9:00 am and noon to minimize the variations in drug metabolizing enzyme gene expression due to the circadian rhythm (Zhang et al., 2009 ).
RNA isolation
Total RNA was isolated from tissues using RNA Bee reagent (Tel-Test Inc., Friendswood, TX) following the manufacturer's protocol. The concentration of total RNA in each sample was quantified spectrophotometrically at 260 nm. Quality of RNA was assessed by running the sample on a denaturing agarose gel and visualizing two discrete 18S and 28S ribosomal RNA bands, with the 28S band double the intensity of the 18S band.
cDNA library preparation and RNA-sequencing
The cDNA library preparation and sequencing of the transcriptome were performed with the help of the KUMC-Genome Sequencing Facility. 
RNA-Seq Data Analysis
After the sequencing platform generated the sequencing images, the pixel-level raw data collection, image analysis, and base calling were performed by Illumina's Real Time Analysis (RTA) software on a Dell PC attached to a HiSeq2000 sequencer. The base call files (*.BCL) were converted to qseq files by the Illumina's BCL Converter, and the qseq files were subsequently converted to FASTQ files for downstream analysis.
The RNA-Seq reads from the FASTQ files were mapped to the mouse mm10 reference genome and the splice junctions were identified by TopHat. The output files in BAM (binary sequence alignment) format were analyzed by Cufflinks to estimate the transcript abundance and the differential expression (Cuffdiff, FDR-BH<0.05). The mRNA abundance was expressed in FPKM (fragments per kilobase of exon per million reads mapped).
Western blotting
Western blots of Cyp2b10 and Cyp3a11 were performed as previously described with minor modifications (Renaud et al., 2011 
Statistical Analysis.
Data are presented as mean ± SEM. Asterisks (*) represent significant differences between CV and GF mice, determined by Cuffdiff, FDR-BH<0.05.
RESULTS
A. Alterations in mRNA expression of hepatic phase-1 drug metabolizing enzymes in GF mice compared to CV mice.
Enzymes involved in phase-1 drug metabolism catalyze hydrolysis, reduction, and oxidation reactions. As compared to the livers of CV mice, carboxylesterases and cytochrome P450s are the most differentially regulated hepatic phase-1 drug metabolizing enzymes in livers of GF mice. were not different between livers of CV and GF mice ( Fig.1.A) .
Carboxylesterases (Ces
Choline Esterase: The mRNAs of Choline esterases, Acetylcholine esterase (Ache) and Butrylcholine esterase (Bche) were similar in the livers of CV and GF mice (Supplement Table 2 ).
Paraoxonase (Pon):
The mRNAs of three paraoxonases Pon1, 2 and 3 were detected in the livers of mice and were similar in CV and GF mice (Supplement Table   2 ).
Alkaline Phosphatase: Three types of alkaline phosphatase were detected in the liver out of which the mRNA of Alpl (tissue non-specific form) was 1.5 fold higher in the livers of GF mice compared to CV mice (Supplement Table 2 ). Table 2 ).
Aldo-keto reductase (Akr): Akrs are NADPH-dependent oxido-reductase enzymes, which reduce aldehydes to alcohols. Akr1c6 was the highest expressed Akr in livers of CV mice, and its mRNA was not altered by the absence of intestinal bacteria.
GF mice had increased mRNAs of Akr1c20 (30%) and Akr1d1 (56%), and decreased Akr1c19 mRNA (31%) in liver, compared to CV mice. The mRNAs of the other Akrs (6 out of 9) were quantitatively similar in livers of both groups of mice ( Fig.1.B Aldehyde dehydrogenase (Aldh). Aldh enzymes catalyze the oxidation of aldehydes to carboxylic acids using NAD + as a cofactor. Aldh1a1 and Aldh2 were the most highly expressed Aldh in livers of both CV and GF mice. Aldh3a2 mRNA was increased (54%) and Aldh1b1 mRNA was decreased (29%) in livers of GF mice compared to CV mice. The mRNAs of other Aldhs (9 out of 11) were expressed at similar levels in CV and GF mice ( 
Aldehyde oxidase (Aox).
Aox is an important class of cytosolic drug metabolizing enzymes with broad substrate specificity. For example, Aox1 plays a role in ethanol-induced liver injury (Shaw and Jayatilleke, 1990). Aox3 was the highest expressed AOX in livers of mice, and its mRNA was similar in livers of CV and GF mice.
Compared to CV mice, Aox1 mRNA was reduced by about one-third in GF mice
Alcohol dehydrogenase (Adh).
The mRNA levels of Adhs were similar in livers of CV and GF mice (Supplement Fig.1 ).
Peroxidases:
The mRNA of Prostaglandin synthases were similar in livers of CV and GF mice. Nine different Glutathione peroxidases (Gpx) were expressed in livers of mice and they were all similarly expressed in CV and GF mice except for the mRNA of Gpx6, which was expressed 4-fold higher in livers of GF mice compared to CV mice.
There were 6 peroxiredoxin enzymes expressed similarly in livers of CV and GF mice (Supplement table 2 ). 
Flavin monooxygenase (Fmo
NADPH-cytochrome P450 oxidoreductase (POR). POR is essential in passing
electrons from NADPH to Cyps located in the endoplasmic reticulum. There is only one POR for the many Cyp enzymes in liver, and GF mice had increased POR mRNA levels (46%) in liver compared to CV mice ( Fig.3 .A).
Cytochrome P450 enzyme (Cyps).
Cyps are c) Cyp2b subfamily-The Cyp2b subfamily was generally lowly expressed in livers of both CV and GF mice. In livers of GF mice, the mRNA of Cyp2b9 was higher (7454%) but Cyp2b10 mRNA was lower (57%) than livers of CV mice ( Fig.3 .A).
d) Cyp2c subfamily-Cyp2c29 was the highest expressed among all the Cyp2c subfamily members in livers of mice, and it was not differentially regulated in the livers of GF mice. However, interestingly, for most other Cyp2c mRNAs that are expressed at intermediary and low levels, the absence of intestinal bacteria resulting in an increase in their mRNA expression, including, Cyp2c38, Cyp2c39, Cyp2c40, Cyp2c50, Cyp2c54, Cyp2c67, Cyp2c68, and Cyp2c69. The mRNA of Cyp2c55 was decreased, and other Cyp2c mRNAs were similar in livers of CV and GF mice ( Fig.3 .B).
e) Cyp2d subfamily-Among the Cyp2d subfamily members, Cyp2d9 is the most highly expressed in livers of mice. GF mice generally had minimal alterations in the mRNAs of the Cyp2d family, except for a moderate increase in Cyp2d13 and 2d37-ps mRNAs. (Fig.3 .C).
f) Cyp2e and Cyp2f -Cyp2e1 and Cyp2f2 were both highly expressed in livers of CV mice and their mRNA levels were similar in GF and CV mice (Fig.4.A) .
g) Cyp3a subfamily-Cyp3a11 was the highest expressed member among the Cyp3a subfamily in livers of CV mice and its expression was decreased the most in livers of GF mice (87%) compared to CV mice. GF mice also have reduced mRNAs of other Cyp3a isoforms, such as Cyp3a16 (86%), Cyp3a44 (87%), and Cyp3a59 (11%).
The mRNA levels of Cyp3a13, Cyp3a25, and Cyp3a41a are similar in livers of CV and GF mice (Fig.4.A) .
h) Cyp4a, 4b, 4f, and 4v subfamilies-In livers of GF mice, most of the differentially expressed Cyp4 genes were up-regulated; for example, the mRNAs of Cyp4a10, Cyp4a14, Cyp4a31, and Cyp4a32 were increased between 150-200%, whereas the mRNA of Cyp4a12b was increased 31% over CV mice. Cyp4f17 mRNA was decreased (38%) in GF mice, and the mRNA levels of other Cyp4 genes were similar in livers of CV and GF mice (Fig.4 .B).
Peptidases, Hydrolases and lipoxygenases:
The mRNA of 4 Serine peptidases (Htra) were lowly expressed in livers of mice and among them Htra4 was expressed 2-fold higher in livers of GF mice compared to CV mice, whereas others were similarly expressed. There were 3 other peptidases, 5 hydrolases and 6 arachidonate lipoxygenases that were expressed similarly in the livers of CV and GF mice (Supplement table 2 hydrocarbons and other carcinogens in the diet and tobacco; therefore polymorphisms in Gsts are associated with differences in the susceptibility to carcinogens. Among Gst family members, the highest expressed Gsts in livers of mice is Gstp1. GF mice have decreased mRNA of Gsta1 (48%), Gstp1 (66%), Gstp2 (64%), and Gstm3 (32%) compared to CV mice. The gene expression of Gstp1 was the second most decreased among the phase-1 and phase-2 genes in livers of GF mice. Short chain fatty acids, which are intestinal bacterial metabolites, are known to induce the expression of Gstp1 in intestine (Stein et al., 1996) , and it appears that they might also increase Gstp1 expression in liver. The mRNA levels of Gstt2 (67%) and Gstt3 (67%) are increased in livers of GF mice compared to CV mice. Other Gsts have similar expression in livers of CV and GF mice. The enzyme glutamate-cysteine ligase catalytic subunit (Gclc) is the rate limiting enzyme for glutathione synthesis. Gclc mRNA levels were also decreased (40%) in livers of GF mice compared to CV mice (Fig.5.A and B) .
UDP-glucuronosyltransferase (Ugt).
Ugts are enzymes that catalyze the transfer of glucuronic acid from the co-substrate uridine diphosphate glucuronic acid to the xenobiotic. Among the Ugts, Ugt2b5, Ugt2b36, and Ugt2b1 are the highest expressed in livers of mice. Livers of GF mice have decreased Ugt2b35 (32%), Ugt2b37 (10%), and Ugt2b38 (11%) mRNA compared to CV mice. The mRNA levels of other Ugts are similar in the livers of CV and GF mice (Fig.5 .C).
Sulfotransferases (Sults).
Sults catalyze the transfer of a sulfonic acid group from the co-substrate PAPS (3'-phosphoadenosine-5'-phosphosulfate) to the xenobiotic.
Sult1a1 is the highest expressed Sult in livers of mice. GF mice have increased Sult1a1
(52%), Sult1b2 (70%), and Sult1d1 (68%) mRNA levels compared to CV mice, whereas the mRNA of Sult5a1 is decreased (48%) (Fig.6.A) .
N-acetyl transferases (Nat). The Nat enzymes catalyze the transfer of an acetyl group from the cofactor acetyl-coenzyme A to an amino group in xenobiotics. This conjugation makes the xenobiotic less water-soluble unlike other phase-2 drug metabolizing reactions that make them more water soluble. Nat6 is the highest expressed Nat enzyme in livers of mice. The mRNAs of all Nat enzymes are similar in livers of GF and CV mice ( Fig.6 .B).
Methyl transferases:
Eight different methyl transferases were expressed in the livers of CV and GF mice. The mRNA of Indolethylamine N-methyltransferase (Inmt) was 1.6 fold higher in the livers of GF mice compared to CV mice, whereas the other methyltransferases were similarly expressed in CV and GF mice livers (Supplement   table 2 ).
Amino acid conjugation:
The enzymes involved in amino acid conjugation of xeno-and endobiotics were expressed similarly in the livers of CV and GF mice (Supplement table 2 
C. Alterations in mRNA expression of transporters
Uptake transporters. In livers of both CV and GF mice, the most highly expressed basolateral uptake transporters is Ntcp, which transports the majority of conjugated bile acids, as well as Oatp1b2, which transports various xenobiotics as well as unconjugated bile acids. Interestingly, in livers of GF mice, the mRNAs of both Ntcp and Oatp1b2 are further up-regulated (46% and 61%, respectively). The Oatp1a1, Oct1, and Ent1 transporters are expressed at intermediary levels, and Ent1 mRNA is 64%
higher in livers of GF mice as compared to CV mice, whereas the mRNAs of Oatp1a1
and Oct1 remain the same in CV and GF mice. Other transporters, including Oatp1a4, Oatp2b1, Oat2, and Asbt, are expressed at relatively low levels, and there is a 64% decrease in Asbt mRNA in livers of GF mice as compared to CV mice (64%), whereas the other three transporters remain at similar levels between CV and GF livers. Mdr1b, the basolateral efflux transporters Ostα and Ostβ, the copper efflux transporter Atp7b, as well as the aminophospholipid flippase Atp8b1. The other transporters, including the phospholipid floppase Mdr2, the xenobiotic efflux transporters Bcrp, Mate1, Mrp3, Mrp6, as well as the sterol efflux transporter dimer Abcg5/g8, and the cholesterol efflux transporter Abca1, are expressed at intermediary levels. In comparison to livers of GF mice, the mRNA of Mrp2 increases 48%, and the mRNAs of Abcg5/g8 increase about 100%, whereas the mRNAs of other efflux transporters appear to be similar between CV and GF mice.
D. Alterations in protein levels of Cyp enzymes
The mRNA of two very important drug metabolizing enzymes, Cyp2b10 and Cyp3a11 were decreased in livers of GF mice compared to CV mice. Therefore, the protein levels of Cyp3a11 and Cyp2b10 in livers of CV and GF mice were quantified.
Similar to their mRNA, both Cyp2b10 and Cyp3a11 protein levels were decreased in livers of GF mice compared to CV mice (Fig. 7) .
Discussion
It is known that, intestinal bacteria can alter the expression of some drug Human CYP3A4 metabolizes more than 60% of all drugs. The mRNA of Cyp3a11, the mouse homolog of CYP3A4, decreased 87% in livers of GF mice compared to CV mice (Fig.4.A) . This together with the protein analysis by western blotting (Fig.8) suggests that intestinal bacteria play an important role in regulating this critical drug metabolizing enzyme.
This study provides a list of drug metabolizing enzymes whose mRNA levels increase or decrease in the absence of intestinal bacteria (Table. 1 The expression of several genes decreased in GF mice and it is likely that these genes are involved in metabolizing intestinal bacterial metabolites, and therefore their expression are higher in the presence of intestinal bacteria. This suggestion is supported by a study that demonstrated that short chain fatty acids can increase the expression of drug metabolizing enzymes in human primary colon cancer cells (Sauer et al., 2007) . In the presence of intestinal bacteria, the liver upregulates some enzymes that conjugate drugs and other xeno-and endobiotics and thus increases their elimination. Subsequently, the conjugated drugs excreted into bile will be deconjugated by intestinal bacterial enzymes, and the unconjugated drug will enter the enterohepatic circulation to be conjugated by the liver enzymes again. In the absence of intestinal bacteria, these hepatic conjugation enzymes are down regulated.
Several genes showed increased expression in GF mice compared to CV mice.
The functions of these enzymes might also be performed by intestinal bacterial enzymes, and therefore, in the presence of intestinal bacteria these enzymes would be down regulated while they would be increased in the absence of intestinal bacteria.
Two groups have earlier performed microarray analysis and described changes in the mRNA of hepatic drug metabolizing enzymes in male GF NMRI and male GF IQI mice (Bjorkholm et al., 2009; Toda et al., 2009) . Their results are contradictory to each other, and our observations are different from both of their reports, possibly due to differences in strains of mice used in the studies. Supplement Table 1 shows the list of hepatic drug metabolizing genes that were altered in GF mice compared to CV mice in this study compared to the two previous microarray studies of GF mice. In this study, the mRNA levels of Cyp2b9 increased markedly (7454%) whereas in the study by Toda 
S c i e n c e 2 2 0 : Total RNA was isolated from livers of adult male conventional (CV) and germ-free (GF) C57BL/6 mice (n = 3 per group). The mRNA quantified by RNA-Seq as described in methods. (* indicates differential expression determined using Cuffdiff (FDR-BH<0.05)).
Dark blue and red bars represent CV and GF male mice, respectively. Cyp-Cytochrome P450, FPKM-fragments per kilobase of exon per million reads mapped. 
